{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nuwellis, Inc.
Is Nuwellis, Inc. technically bullish or bearish?
As of August 1, 2025, Nuwellis, Inc. shows a mildly bullish technical trend despite mixed indicators, underperforming the S&P 500 with a year-to-date return of -91.89%.
Nuwellis, Inc. Stock Plummets to New 52-Week Low of $3.65
Nuwellis, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company reported a quarterly net sales figure of USD 1.73 million and a substantial pre-tax loss, indicating ongoing operational challenges and a weak financial position.
Is Nuwellis, Inc. overvalued or undervalued?
As of March 23, 2017, Nuwellis, Inc. is considered overvalued and carries a "risky" valuation grade due to its negative P/E ratio and significantly low EV to EBITDA and EV to EBIT ratios compared to its peers.
Is Nuwellis, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is mildly bearish, influenced by daily moving averages and weekly KST showing bearish signals, despite some mildly bullish indications from the MACD and mixed signals from the RSI.
Who are in the management team of Nuwellis, Inc.?
As of March 2022, the management team of Nuwellis, Inc. includes Chairman John Erb, Lead Independent Director Warren Watson, and Independent Directors Steven Brandt, Maria Costanzo, Jon Salveson, and Gregory Waller.
What does Nuwellis, Inc. do?
Nuwellis, Inc. is a micro-cap medical device company specializing in ultrafiltration therapy. As of March 2025, it reported net sales of $2 million and a net loss of $3 million, with a market cap of $1.30 million.
How big is Nuwellis, Inc.?
As of Jun 18, Nuwellis, Inc. has a market capitalization of 1.30 million, with net sales of 8.78 million and a net profit of -9.84 million over the last four quarters. Shareholder's funds are reported at 6.53 million, and total assets amount to 9.86 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
